Clinical significance of the RT-PCR positive sentinel node in melanoma

Journal of Surgical Oncology

Volumn 95, Issue 7, 2007, Pages 546-554

  Temple, C L F ^a,d,f   Snell, L J ^b   Power, S M ^c   Parfitt, J R ^a   Scilley, C ^a   Engel, C J ^d   Shum, D ^e   Chakrabarti, S ^a   Joseph, M G ^a   Lohmann, R C ^d   Ainsworth, P ^d  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c WESTERN UNIVERSITY   (Canada)

^d LONDON REGIONAL CANCER PROGRAM   (Canada)

^e Windsor Hospital   (Canada)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Melanoma; RT PCR; Sentinel node; Survival; Tyrosinase

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CHI SQUARE TEST; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MELANOMA; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE BIOPSY; TUMOR RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; LYMPH NODE; LYMPH NODE METASTASIS; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SKIN TUMOR;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 34347371847     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20741     Document Type: Article

References (53)

1. Balch CM: Final version of the American joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648.
2. Morton DL, Wen DR, Wong JH, et al.: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-399.
3. Reintgen DS, Conrad AJ: Detection of occult melanoma cells in sentinel lymph nodes and blood. Semin Oncol 1997;24:S4-S11.
4. Wang X, Heller R, VanVoorhis N: Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994;220:768-774.
5. Prichard RS, Dijkstra B, McDermott EW, et al.: The role of molecular staging in malignant melanoma. EJSO 2003;29:306-314.
6. Spanknebel K, Coit DG, Bieligk SC, et al.: Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology. Am J Surg Pathol 2005;29:305-317.
7. Bieligk SC, Ghossein R, Bhattacharya S, et al.: Detection of tyrosinase mRNA by reverse transcription-polymerase chain reaction in melanoma sentinel nodes. Ann Surg Oncol 1999;6:232-240.
8. Ghossein RA, Rosai J: Polymerase chain reaction in the detection of micrometastases and circulating tumor cells. Cancer 1996;78:10-16.
9. Van der Velde-Zimmerman D, Roijers JFM, Bouwens-Rombouts A, et al.: Molecular test for the detection of tumor cells in blood and sentinel nodes of melanoma patients. Am J Pathol 1996;149:759-764.
10. Smith B, Selby P, Southgate J, et al.: Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991;338:1227-1229.
11. Rea S, O'Sullivan ST: The polymerase chain reaction and its application to clinical plastic surgery. J Plast Reconstr Aesthet Surg 2006;59:113-121.
12. Battayani Z, Grob JJ, Xerri L, et al.: Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol 1995;131:443-447.
13. McMasters KM, Noyes RD, Reintgen DS, et al.: Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol 2004;86:212-223.
14. Shivers S, Alsarraj M, Guiliano R, et al.: Molecular staging of melanoma. Ann Surg Oncol 2004;11:953-954.
15. Blaheta HJ, Birgit S, Breuninger H, et al.: Detection of melanoma micrometastasis in sentinel nodes by reverse transcription-polymerase chain reaction correlates with tumor thickness and is predictive of micrometastatic disease in the lymph node basin. Am J Surg Pathol 1999;23:822-828.
16. Messina JL, Glass LF: Pathologic examination of the sentinel lymph node. J Florida MA 1997;84:153-156.
17. van Diest PJ, Peterse HL, Borgstein PJ, et al.: Pathological investigation of sentinel lymph nodes. Eur J Nucl Med 1999;26:S43-S49.
18. Bostick PJ, Morton DL, Turner RR, et al.: Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 1999;17:3238-3244.
19. Carson KF, Wen DR, Li PX, et al.: Nodal nevi and cutaneous melanomas. Am J Surg Pathol 1996;20:834-840.
20. Martinez SR, Hoon DSB: Molecular markers in malignant cutaneous melanoma: Gift horse or one-trick pony? J Cell Biochem 2005;96:473-483.
21. Prichard RS, Dijkstra B, McDermott EW, et al.: The role of molecular staging in malignant melanoma. Eur J Surg Oncol 2003;29:306-314.
22. Brossart P, Keilholz U, Willhauk M, et al.: Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol 1993;101:887-889.
23. Voit C, Kron M, Rademaker J, et al.: Molecular staging in stage II and III melanoma patients and its effect on long-term survival. J Clin Oncol 2005;23:1218-1227.
24. Koyanagi K, Kuo C, Nakagawa T, et al.: Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: Relation to disease stage in melanoma patients. Clin Chem 2005;51:981-988.
25. Boldin I, Langmann G, Richtig E, et al.: Five-year results of prognostic value of tyrosinase in peripheral blood of uveal melanoma patients. Melanoma Res 2005;15:503-507.
26. Glumac N, Snoj M, Hocevar M, et al.: Prognostic significance of tyrosinase mRNA detected by nested RT-PCR in patients with malignant melanoma. Neoplasma 2006;53:9-14.
27. Brossart P, Schimer JW, Kruger S, et al.: A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res 1995;55:4065-4068.
28. Ranieri JM, Wagner JD, Wiebke EA, et al.: Lack of prognostic importance of reverse-transcriptase polymerase chain reaction detection of circulating messenger RNA in patients with melanoma. Plast Reconstr Surg 2005;115:1058-1063.
29. Schmidt H, Sorensen BS, Sjoegren P, et al.: Circulating tyrosinase and MART-1 mRNA does not independently predict relapse or survival in patients with AJCC Stage I-II Melanoma. J Invest Dermatol 2006 Apr;126(4):849-854.
30. Schmidt H, Sorensen BS, Fode K, et al.: Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy. Melanoma Res 2005;15:409-416.
31. Tsao H, Nadiminti U, Sober AJ, et al.: A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma. Arch Dermatol 2001;137:325-330.
32. Quaglino P, Savoia P, Osella-Abate S, et al.: RT-PCR tyrosinase expression in the peripheral blood of melanoma patients. Expert Rev Mol Diagn 2004;4:727-741.
33. Blaheta HJ, Ellwanger U, Schittek B, et al.: Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol 2000;114:637-642.
34. Li W, Stall A, Shivers SC, et al.: Clinical relevance of molecular staging for melanoma. Comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann Surg 2000;231:795-803.
35. Denninghoff VC, Kahn AG, Falco J, et al.: Sentinel lymph node. Detection of micrometastases of melanoma in a marker study. Mol Diagn 2004;8:253-258.
36. Shivers SC, Wang X, Li W, et al.: Molecular staging of malignant melanoma: Correlation with clinical outcome. JAMA 1998;280:1410-1415.
37. Kuo CT, Hoon DSB, Takeuchi H, et al.: Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol 2003;21:3566-3572.
38. Ulrich J, Bonnekoh B, Bockelmann R, et al.: Prognostic significance of detecting micrometastases by tyrosinase RT/PCR in sentinel lymph node biopsies: Lessons from 322 consecutive melanoma patients. European J Cancer 2004;40:2812-2819.
39. Giese T, Engster M, Mansmann U, et al.: Quantification of melanoma micrometastases in sentinel lymph nodes using real-time RT-PCR. J Invest Dermatol 2005;124:633-637.
40. Romanini A, Manca G, Pellegrino D, et al.: Molecular staging of the sentinel lymph node in melanoma patients: Correlation with clinical outcome. Annals Oncol 2005;16:1832-1840.
41. Goydos JS, Patel KN, Shih WJ, et al.: Patterns of recurrence in patients with melanoma and histologically negative but RT-PCR-positive sentinel lymph nodes. J Am Coll Surg 2003;196:196-204.
42. Rimoldi D, Lemoine R, Kurt AM, et al.: Detection of micrometastases in sentinel lymph nodes from melanoma patients: Direct comparison of multimarker molecular and immunopathological methods. Melanoma Res 2003;13:511-520.
43. Takeuchi H, Morton DL, Kuo C, et al.: Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol 2004;22:2671-2680.
44. Scoggins CR, Ross MI, Reintgen DS, et al.: Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol 2006;24:2849-2857.
45. Mangas C, Hilari JM, Paradelo C, et al.: Prognostic significance of molecular staging study of sentinel lymph nodes by reverse transcriptaserpolymerase chain reaction for tyrosinase in melanoma patients. Ann Surg Oncol 2006;13:910-918.
46. Kammula US, Ghossein R, Bhattacharya S, et al.: Serial follow-up and the prognostic significance of reverse transcriptase-polymerase chain reaction-staged sentinel lymph nodes from melanoma patients. J Clin Oncol 2004;22:3989-3996.
47. Leiter U, Meier F, Schittek B, et al.: The natural course of cutaneous melanoma. J Surg Oncol 2004;86:172-178.
48. Erik CD, Lotem M, Gimon Z, et al.: Molecular detection of MART-1, tyrosinase and MIA in peripheral blood, lymph nodes and metastatic sites of stage III/IV melanoma patients. Melanoma Res 2004;14:361-365.
49. Gradilone A, Ribuffo D, Silvestri I, et al.: Detection of melanoma cells in sentinel lymph nodes by reverse transcriptase-polymerase chain reaction: Prognostic significance. Annals Surg One 2004;11:983-987.
50. Shivers SC, Li W, Haddad F, et al.: Editorial: Molecular staging of melanoma. Annals Surg Oncol 1999;6:225-226.
51. Hoon DSB, Wang Y, Dale PS, et al.: Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995;13:2109-2116.
52. Wascher RA: Pitfalls in the use of RT-PCR as a prognostic indicator in melanoma. J Clin Oncol 2005;23:3863-3864.
53. Abrahamsen HN, Sorensen BS, Nexo E, et al.: Pathologic assessment of melanoma sentinel nodes: A role for molecular analysis using quantitative real-time reverse transcription-PCR for MART-1 and tyrosinase messenger RNA. Clin Cancer Res 2005;11:1425-1433.